MeSH D006528 - hepatocellular carcinoma
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Teva | Sorafenib | Sorafenib |  | 2020-11-12 |  |  |
| Mylan | Sorafenib | Sorafenib |  | 2020-09-10 |  |  |
| Roche | Ribavirin, Peginterferon alfa-2a | Pegasys Copegus |  | 2004-06-04 |  |  |
| Interferon alfa-2a | Roferon-A |  | 1986-06-04 |  |  | |
| Atezolizumab | Tecentriq |  | 2017-09-20 | $4,406.336 M | Q4/22-Q3/23 | |
| AstraZeneca | Tremelimumab | Imjudo |  | 2022-10-21 | $13 M | Y2024 |
| Tremelimumab | Tremelimumab AstraZeneca |  | 2023-02-20 |  |  | |
| Merck & Co | Interferon alfa-2b | Intron A |  | 1986-06-04 |  |  |
| Interferon alfa-2b | IntronA |  | 2000-03-09 |  |  | |
| Peginterferon alfa-2b | PegIntron |  | 2001-01-19 |  |  | |
| Ribavirin, Peginterferon alfa-2b | PegIntron/ Rebetol Combo Pack |  | 2008-06-13 |  |  | |
| Interferon alfa-2b | Viraferon |  | 2000-03-09 |  |  | |
| Peginterferon alfa-2b | ViraferonPeg |  | 2000-05-28 |  |  | |
| Bayer | Sorafenib | Nexavar | 2023-02-11 | 2005-12-20 |  |  |
| Regorafenib | Stivarga | 2022-06-28 | 2012-09-27 |  |  | |
| Dr Reddys Laboratories | Sorafenib | Sorafenib |  | 2022-06-07 |  |  |
| Accord Healthcare | Sorafenib | Sorafenib Accord |  | 2022-11-09 |  |  |
| Horizon Therapeutics Public | Interferon gamma-1b | Actimmune |  | 1999-02-25 | $122.816 M | Q3/22-Q2/23 |
| Pharma& | Peginterferon alfa-2a | Pegasys |  | 2002-10-16 |  |  |
1
2
>
Clinical Trials
Historical Success Rate
Phase 1
74%51/69
Phase 2
25%25/100
Phase 3
30%11/37
Approved: 8Overall Success rate: 5%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use